ORIGINAL ARTICLE

Prognostic value of the long noncoding RNA AFAP1-AS1 in cancers*

Lixiu Zhu¹, Jiawen Yan¹ (Co-first author), Guoqiang Xu¹ (Co-first author), Qiaoli Wang² (Co-first author), Tianrui Xu¹, Ruixue Cao¹, Chuanzheng Sun³ (\boxtimes), Yan Xi³ (\boxtimes), Wei Xiong¹ (\boxtimes)

- ¹ Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China
- ² Department of Radiotherapy, People's Hospital of Yuxi City, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi 653100, China
- ³ Department of Head and Neck Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China

Abstract	Objective This meta-analysis explored whether the expression of actin filament-associated protein 1 antisense RNA 1 (<i>AFAP1-AS1</i>) is related to the prognosis and clinicopathological features of patients with cancer.
	Methods PubMed, EMBASE, and Cochrane Library were systematically searched. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the prognostic value based on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Odds ratios (ORs) with 95% CIs were used to determine the relationships between <i>AFAP1-AS1</i> and clinicopathological features, such as large tumor size (LTS), high tumor stage (HTS), poor histological grade (PHG), lymph node metastasis (LNM), and distant metastasis (DM).
	Results Thirty-five eligible articles and 3433 cases were analyzed. High <i>AFAP1-AS1</i> expression, compared to low <i>AFAP1-AS1</i> expression, correlated with significantly shorter OS (HR = 2.15, 95% CI = $1.97-2.34$, $P < 0.001$), DFS (HR = 1.37 , 95% CI = $1.19-1.57$, $P < 0.001$), and PFS (HR = 1.97 , 95% CI = $1.56-2.50$, $P < 0.001$) in patients with cancer. In various cancers, elevated <i>AFAP1-AS1</i> expression was significantly associated with LTS (OR = 2.76 , 95% CI = $2.16-3.53$, $P < 0.001$), HTS (OR = 2.23 , 95% CI = $1.83-2.71$, $P < 0.001$), and PHG (OR = 1.39 , 95% CI = $1.08-1.79$, $P = 0.01$) but not LNM (OR = 1.59 , 95% CI = $0.88-2.85$, $P = 0.12$) or DM (OR = 1.81 , 95% CI = $0.90-3.66$, $P = 0.10$).
Received: 14 June 2022	Conclusion High <i>AFAP1-AS1</i> expression was associated with prognostic and clinicopathological features, suggesting that <i>AFAP1-AS1</i> is a prognostic biomarker for human cancers.
Revised: 29 August 2022	Key words: Iong noncoding RNA (IncRNA); actin filament-associated protein 1 antisense RNA 1 (AFAP1-
Accepted: 27 March 2023	AS1); prognostic; meta-analysis

Cancer is an important factor that affects human health and is a leading cause of death worldwide. According to recent epidemiological statistics, there are an estimated 19.3 million new cancer cases and nearly 10.0 million cancer deaths worldwide each year ^[1]. Global cancer cases are expected to reach 28.4 million cases in 2040, an increase of 47% compared to that in 2020, which may further increase the economic burden ^[1]. With advancements in medicine and science, cancer deaths have decreased; however, the five-year survival rate is still inadequate. Although many studies have focused on biomarkers for cancer diagnosis and prognosis, the results have not been optimistic. Therefore, new prognostic biomarkers are needed to drive cancer development.

Long noncoding RNAs (lncRNAs), which are transcriptional regulatory factors that operate in cis or trans, are defined as transcripts that do not encode proteins of more than 200 nucleotides ^[2]. lncRNAs are associated

Correspondence to: Chuanzheng Sun. Email: scz007@126.com; Yan Xi. Email: xiyan616@126.com; Wei Xiong. Email: panda_wei_wei@163.com

^{*} Supported by a grant from the "Ten Thousand Plan" Youth Talent Project in Yunnan Province (no grant number is applicable).

^{© 2023} Huazhong University of Science and Technology

with a variety of functions, such as the regulation of epigenetic, transcriptional, and post-transcriptional mechanisms ^[3-4]. Mounting evidence has shown that lncRNAs are dysregulated in various cancers and play important roles in invasion and metastasis, suggesting that lncRNAs may act as regulators of gene expression and affect tumor progression ^[5]. Several studies have shown that lncRNAs have multiple functions in many cellular processes that may play important roles in carcinogenesis and cancer progression. Evidence supporting the use of abnormally expressed lncRNAs as biomarkers of various human cancers has facilitated the development of lncRNA-based diagnostic tools and treatments.

Actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1), the antisense transcript of the AFAP1 gene, has a length of 6810 bp and is located in the 4p16.1 region of the human genome^[6]. AFAP1-AS1, originally identified in 2013, has been shown to be present in esophageal adenocarcinoma^[7]. Previous studies have indicated that lncRNAs can be used as molecular markers of location, time, developmental stage, and gene expression regulation ^[8]. Among lncRNAs with upregulated expression in cancer, AFAP1-AS1 plays a carcinogenic role in different human cancer cells as well as an important regulatory role. Studies have shown that in hepatocellular carcinoma (HCC), the knockout of AFAP1-AS1 with an si-AFAP1-AS1 construct can reduce proliferation and invasion in vitro and in vivo, induce apoptosis, and block the cell cycle in the S phase [9]. In addition, lncRNAs can be used as guides to recruit chromatin-modifying enzymes to target genes [8]. Furthermore, AFAP1-AS1 recruited LSD1 to the promoter region of HBP1 and inhibited its transcription by mediating H3K4me2 demethylation ^[10]. A previous study showed that AFAP1 expression could be regulated by DNA methylation [11]. lncRNAs also function by interacting with various RNA-binding proteins, leading to the inactivation or activation of gene expression through chromosomal reprogramming, DNA methylation, RNA decay, and histone modification^[12]. In particular, AFAP1-AS1, an oncogene, binds to EZH2 to inhibit p21 transcription and promote tumor cell formation^[12].

Notably, these lncRNAs have more functions than those of the aforementioned lncRNAs. Studies have shown that lncRNAs can interfere with transcriptional mechanisms and maintain the structure of nuclear spots ^[13]. In addition, lncRNAs may hybridize with DNA and affect chromatin. Furthermore, lncRNAs interact with chromatin proteins to promote or inhibit their binding and activity in target regions ^[14]. Unfortunately, to date, investigations of *AFAP1-AS1* have been insufficient, and the above functions have not yet been identified for this lncRNA. In addition, the basic mechanisms and related functions of *AFAP1-AS1* remain unclear.

AFAP1-AS1 is a well-known lncRNA that is overexpressed in several malignancies. AFAP1-AS1 is involved in cell proliferation, angiogenesis, invasion, and metastasis of various cancers^[15]. In addition, AFAP1-AS1 can be used as a diagnostic marker for various cancers. Moreover, high expression of AFAP1-AS1 is closely related to clinical prognostic indicators, including overall survival (OS) [16], disease-free survival (DFS) [17], and progression-free survival (PFS)^[10]. A meta-analysis reported that the AFAP1-AS1 expression level was associated with clinical outcomes, including survival, tumor size and stage, and histological differentiation^[18]. As the literature included in this article has been updated, we performed a meta-analysis to evaluate the prognostic utility of AFAP1-AS1 in patients with cancer in a clinical setting.

Methods

Literature search

We searched for relevant articles in the PubMed, EMBASE, and Cochrane Library electronic databases. The search terms were as follows: (("Neoplasia" OR "Neoplasias" OR "Neoplasm" OR "Tumors" OR "Tumor" OR "Cancer" OR "Cancers" OR "Malignancy" OR "Malignancies" OR "Malignant Neoplasms" OR "Malignant Neoplasm" OR "Neoplasm, Malignant" OR "Neoplasms, Malignant" OR "Benign Neoplasms" OR "Neoplasms, Benign" OR "Benign Neoplasm" OR "Neoplasm, Benign" OR "acral tumor" OR "acral tumour" OR "embryonal and mixed neoplasms" OR "germ cell and embryonal neoplasms" OR "glandular and epithelial neoplasms" OR "hormone-dependent neoplasms" OR "neoplasia" OR "neoplasms" OR "neoplasms by histologic type" OR "neoplasms, cystic, mucinous, and serous" OR "neoplasms, embryonal and mixed" OR "neoplasms, germ cell and embryonal" OR "neoplasms, glandular and epithelial" OR "neoplasms, hormone-dependent" OR "neoplasms, post-traumatic" OR "neoplastic disease" OR "neoplastic entity" OR "neoplastic mass" OR "posttraumatic neoplasms" OR "tumor" OR "tumoral entity" OR "tumoral mass" OR "tumorous entity" OR "tumorous mass" OR "tumour" OR "tumoural entity" OR "tumoural mass" OR "tumourous entity" OR "tumourous mass") OR ("Neoplasms" [Mesh])) AND (("lncRNA-AFAP1-AS1, human" OR "AFAP1 antisense RNA, human" OR "long non-coding RNA AFAP1-AS1" OR "IncRNA AFAP1-AS1" OR "AFAP1-AS1" OR "AFAP1 antisense RNA 1" OR "actin filament-associated protein 1 antisense RNA1") OR ("AFAP1-AS1 long noncoding RNA, human" [Supplementary Concept])). The search was conducted on November 21, 2020. To obtain potential eligible papers, we manually reviewed the reference lists to identify additional relevant articles.

Inclusion and exclusion criteria

The following inclusion criteria were used: (1) articles with histopathologically confirmed carcinoma; (2) articles in which the expression levels of *AFAP1-AS1* in tissues of cancer patients were determined; (3) articles in which patients were divided into two distinct groups, including high- and low-expression groups; (4) articles that statistically analyzed patient prognosis or clinicopathological features; and (5) articles written in English.

The following exclusion criteria were applied: (1) articles not related to carcinoma; (2) letters, expert opinions, case reports, editorials, and reviews; (3) studies with duplicate data; and (4) studies without usable data or data from animal experiments.

Data extraction and quality assessment

Two reviewers (Lixiu Zhu and Guoqiang Xu) independently searched the databases for eligible articles based on the inclusion and exclusion criteria. Tianrui Xu and Ruixue Cao evaluated the quality of the included studies. Information was independently extracted from the included studies by two operators (Jiawen Yan and Qiaoli Wang). Upon disagreement, three authors (Lixiu Zhu, Guoqiang Xu, and Jiawen Yan) discussed and resolved the issue. The following information was collected for each qualified article: first author's last name, year of publication, country, tumor type, sample size, detection method, reference gene, cutoff values, number of patients with large tumor size (LTS), high tumor stage (HTS), poor histological grade (PHG), lymph node metastasis (LNM), and distant metastasis (DM) between the high and low expression groups. For studies that did not provide hazard ratios (HRs) and 95% confidence intervals (CIs), widely proven and accepted scientific methods were used, and Engauge Digitizer 10.8 was used to extract data from the survival curve [19-20]. The data were entered into an HR calculation spreadsheet developed by Tierney et al^[21]. The HRs, standard errors (SE), and corresponding 95% CIs were then estimated according to the curve.

The Newcastle-Ottawa Scale (NOS) was used to appraise the quality of the literature; this method adopts a "star" rating system, with the full credit of 9 stars. It is generally used to judge the quality of a methodology, including the selection (0–4 stars), comparability (0–2 stars), and results (0–3 stars) ^[22]. Articles with scores > 5 were considered high quality; other articles were considered low quality.

External validation

Transcriptome and clinical data of 33 tumors were downloaded from the UCSC Xena database (http://xena. ucsc.edu/). The data were collated and the expression levels of *AFAP1-AS1* in each neoplastic tissue were

extracted. According to the median expression level of AFAP1-AS1 in each tumor, each cohort was divided into high and low expression groups using R. Cox regression analysis was used to evaluate the relationship between AFAP1-AS1 expression and OS, DFS, and PFS in patients with tumors. The results were presented as forest maps. Statistical significance was set at P < 0.05.

Statistical analysis

Review Manager version 5.4 and R version 4.1.1 were used for all statistical analyses. The combined HRs and 95% CIs were used to estimate the prognostic significance of AFAP1-AS1 in terms of OS, DFS, and PFS in various cancers. Comprehensive odds ratios (ORs) and 95% CIs were used to estimate the association between AFAP1-AS1 and clinicopathological features, such as tumor size and stage, histological grade, LNM, and DM. Heterogeneity between articles was detected by the l^2 test, and both P < 0.1 and I^2 values > 50% were considered to indicate obvious heterogeneity. Therefore, randomand fixed-effects models were selected to analyze the data according to heterogeneity. The OS, DFS, and PFS of patients with different types of tumors were analyzed using R, and HR values were calculated based on the Cox proportional hazards model. Additionally, publication bias was measured using Begg's funnel plots.

Results

Study selection

After searching the PubMed, Embase, and Cochrane Library databases, a total of 228 studies were found; 94 studies were deleted due to duplication, of which 88 were reclassified as unqualified by automatic tools and six were reclassified as unqualified by manual assessment. Further exclusions were made by reviewing the full texts of the remaining 134 articles. After examining the titles and abstracts, 58 irrelevant studies were excluded. Further, four articles could not be retrieved and were excluded. Next, 37 articles were excluded: six meta-analyses or reviews, 30 articles with incomplete data, and one article written in Chinese. Finally, we included 35 studies that met the criteria^[9-10, 12, 16-17, 23-52], with a total of 3433 patients. The flow diagram is shown in Fig. 1.

Characteristics of the included studies

All the included studies were conducted in China between 2015 and 2020. Patient sample sizes in the 35 studies ranged from 30 to 256, with an average sample size of 143. In all but one ^[25], the expression of the lncRNA *AFAP1-AS1* was measured by real-time quantitative polymerase chain reaction (qRT-PCR) ^[9–10, 12, 16–17, 23–24, 26-52]. The genes used for the normalization of *AFAP1-AS1* expression were not consistent, and *U6*^[27, 36, 45], *GAPDH*




Fig. 1 Flowchart of the study search and screening in this meta-analysis

[9-10, 12, 16, 23-24, 26, 28-29, 33-35, 37-38, 40-41, 43-44, 46-51], β -actin [30-32, ^{39, 42, 52]}, and *HPRT1*^[17] were used. The cutoff value was expressed in various forms; however, 13 studies did not provide a clear cutoff value. With regard to prognostic outcomes, OS was reported in 33 studies [9-10, 12, 16, 23-26, ^{28-32, 34-38, 40-46, 48, 50-52]}, DFS in six studies ^[17, 26, 32-33, 38, 42]; and PFS in four studies ^[10, 24, 30, 36]. In this meta-analysis, a total of 25 cancers were assessed: non-small cell lung cancer (NSCLC), endometrial carcinoma (EC), triple-negative breast cancer (TNBC), tongue squamous cell carcinoma (TSCC), prostate cancer (PCA), clear cell renal cell carcinoma (ccRCC), retinoblastoma (RB), bladder cancer (BCA), colon cancer (CC), lung adenocarcinoma (LUAD), esophageal squamous cell carcinoma (ESCC), lung cancer (LC), pancreatic ductal adenocarcinoma (PDAC), ovarian cancer (OC), gastric cancer (GC), colorectal cancer (CRC), gallbladder cancer (GBC), cholangiocarcinoma (CCA), nasopharyngeal carcinoma (NPC), breast cancer (BC), glioma, osteosarcoma (OS), HCC, thyroid cancer

(TC), and pancreatic cancer (PC). The NOS score for the quality assessment of all studies ranged from 5 to 8, and the quality assessment achieved a good consensus between the two reviewers.

Association between AFAP1-AS1 and prognosis

Association between AFAP1-AS1 and shorter OS

Of the 35 included studies, 33 reported prognosis in terms of OS according to *AFAP1-AS1* expression levels, with a total of 3141 patients. A fixed-effects model was used because of non-significant heterogeneity ($I^2 = 12\%$, $P_Q = 0.27$). The pooled results showed that high expression of *AFAP1-AS1*, compared to low *AFAP1-AS1* expression, was associated with shorter OS (HR = 2.15, 95% CI: 1.97–2.34, Fig. 2).

Association between AFAP1-AS1 and shorter DFS and PFS

According to AFAP1-AS1 expression levels DFS was reported for 978 patients in six articles and PFS was

				Hazard ratio	Hazard ratio
Study or subgroup	log [Hazard ratio]	SE	Weight	IV. Fixed. 95% CI	IV. Fixed. 95% CI
Bo 2018	0.4318	0.1906	5.2%	1.54 [1.06, 2.24]	
Chen 2018	1.0613	0.2618	2.8%	2.89 [1.73, 4.83]	
Dai 2018	0.4121	0.6291	0.5%	1 51 [0 44, 5 18]	
Deng 2015	2.1913	0.5383	0.7%	8.95 [3.12, 25.70]	
Fei 2020	0.7608	0.2769	2.5%	2 14 [1 24, 3 68]	
Feng 2017	1.1985	0.3869	1.3%	3.32 [1.55, 7.08]	
Fu 2016	0.5176	0.3464	1.6%	1.68 [0.85, 3.31]	
Gui 2020	0.174	1.0238	0.2%	1.19 [0.16, 8.85]	
Hao 2018	1.2804	0.5097	0.7%	3.60 [1.32, 9.77]	
Leng 2018	1.2754	0.5369	0.7%	3.58 [1.25, 10.25]	
Li 2016	0.8973	0.0696	39.1%	2.45 [2.14, 2.81]	
Li 2018	0.4383	0.5015	0.8%	1.55 [0.58, 4.14]	
Lu 2016	0.3988	0.2864	2.3%	1.49 [0.85, 2.61]	
Lu 2017	0.131	0.5218	0.7%	1.14 [0.41, 3.17]	
Ma 2016	0.892	0.3212	1.8%	2.44 [1.30, 4.58]	
Ma 2019	0.3507	0.5126	0.7%	1.42 [0.52, 3.88]	
Ma 2020	0.3784	0.3537	1.5%	1.46 [0.73, 2.92]	
Mu 2019	0.9821	0.6904	0.4%	2.67 [0.69, 10.33]	
Tang 2017	0.0677	0.3882	1.3%	1.07 [0.50, 2.29]	
Tang 2018	0.8755	0.2165	4.0%	2.40 [1.57, 3.67]	
Wang 2016	0.8578	0.3844	1.3%	2.36 [1.11, 5.01]	
Wang 2018 (1)	0.4574	0.4773	0.8%	1.58 [0.62, 4.03]	
Wang 2018 (2)	1.1939	0.4339	1.0%	3.30 [1.41, 7.72]	
Wang 2019	0.9895	0.5419	0.6%	2.69 [0.93, 7.78]	
Ye 2015	0.6931	0.2082	4.4%	2.00 [1.33, 3.01]	
Yin 2018	0.9163	0.3336	1.7%	2.50 [1.30, 4.81]	
Yu 2019	0.6259	0.2615	2.8%	1.87 [1.12, 3.12]	
Zeng 2015 (1)	0.6419	0.2474	3.1%	1.90 [1.17, 3.09]	
Zeng 2015 (2)	1.0647	0.3229	1.8%	2.90 [1.54, 5.46]	
Zhang 2016	0.3859	0.2036	4.6%	1.47 [0.99, 2.19]	
Zhang 2018	0.3646	0.3128	1.9%	1.44 [0.78, 2.66]	
Zhao 2018	0.7178	0.2861	2.3%	2.05 [1.17, 3.59]	
Zhong 2020	0.5365	0.4205	1.1%	1 71 [0 75, 3 90]	
Zhou 2016	0.6355	0.2208	3.9%	1.89 [1.22, 2.91]	
Total (95% CI)			100%	2.15 [1.97, 2.34]	
	= 37.55, df = 33 (<i>P</i> =		12%		0.01 0.1 1 10 100
Test for overall effect	ct: Z = 17.58 (<i>P</i> < 0.0	0001)			Favours [high expression] Favours [low expression]

Fig. 2 Forest plot of HRs for the association between high AFAP1-AS1 expression and OS

reported for 397 patients in four articles. There was no apparent heterogeneity among the studies (DFS: $I^2 = 0\%$, $P_Q = 0.51$; PFS: $I^2 = 0\%$, $P_Q = 0.65$); thus, a fixed-effects model was used to estimate the pooled HRs and the corresponding 95% CI values. These data indicated that the *AFAP1-AS1* expression level was associated with DFS (pooled HR = 1.37, 95% CI: 1.19–1.57, Fig. 3) and PFS (pooled HR = 1.97, 95% CI: 1.56–2.50, Fig. 4) in patients with various tumors.

Association between *AFAP1-AS1* and clinicopathological features


In this meta-analysis, 16 eligible studies with 1219 patients reported *AFAP1-AS1* expression levels according to LTS data. A fixed-effects model was adopted to account for the data because there was no apparent heterogeneity ($I^2 = 17\%$, $P_Q = 0.26$). This analysis showed that there

may be a significant positive association between the high expression level of AFAP1-AS1 and LTS (OR = 2.76, 95% CI: 2.16–3.53, Fig. 5). Secondly, twenty-one eligible studies involving 1987 patients reported AFAP1-AS1 expression levels according to HTS data. No obvious heterogeneity was detected ($I^2 = 42\%$, $P_Q = 0.02$); therefore, a fixed-effects model was selected, and a pooled OR of 2.23 was obtained (95% CI: 1.83-2.71, Fig. 6). Fifteen eligible studies with 1339 patients reported AFAP1-AS1 expression levels according to the histological grade. We selected a fixed-effects model because no significant heterogeneity was observed ($\hat{P} = 45\%$, $P_Q = 0.03$). The integrated data suggested that elevated AFAP1-AS1 expression predicted PHG in various cancers (OR = 1.39, 95% CI: 1.08–1.79, Fig. 7). Thirteen eligible studies with 1202 patients reported AFAP1-AS1 expression levels in LNM. Because there was significant statistical

				Hazard ratio	Hazard ratio
Study or subgroup	log [Hazard ratio]	SE	Weight	IV. Fixed. 95% CI	IV. Fixed. 95% CI
Bo 2018	0.2231	0.2151	11.2%	1.25 [0.82, 1.91]	+
He 2018	0.2469	0.0888	65.7%	1.28 [1.08, 1.52]	
Lu 2016	0.5539	0.2025	12.6%	1.74 [1.17, 2.59]	
Wang 2016	0.7514	0.3673	3.8%	2.12 [1.03, 4.35]	
Zhang 2018	0.2624	0.3232	5.0%	1.30 [0.69, 2.45]	
Zhuang 2017	0.7793	0.5652	1.6%	2.18 [0.72, 6.60]	
Total (95% CI)			100%	1.37 [1.19, 1.57]	•
Heterogeneity: Chi ²	= 4.27, df = 5 (<i>P</i> = 0.1	51); l² = 0%	, o		
Test for overall effect	ct: Z = 4.33 (P < 0.000	01)			0.01 0.1 1 10 100
					Favours [high expression] Favours [low expression]

Fig. 3 Forest plot of HRs for the association between high AFAP1-AS1 expression and DFS

				Hazard ratio	Hazard ratio	
Study or subgroup	log [Hazard ratio]	SE	Weight	IV. Fixed. 95% CI	I IV. Fixed. 95% CI	
Li 2018	0.8109	0.3929	9.5%	2.25 [1.04, 4.86]]	
Ye 2015	0.6881	0.1831	43.7%	1.99 [1.39, 2.58]]	
Yu 2019	0.9361	0.2987	16.4%	2.55 [1.42, 4.58]]	
Zhou 2016	0.4867	0.2198	30.3%	1.63 [1.06, 2.50]]	
Total (95% CI)			100%	1.97 [1.56, 2.50]	1	
0,	= 1.63, df = 3 (P = 0.0)				0.01 0.1 1 10 1	100
rest for overall effec	ot: Z = 5.61 (<i>P</i> < 0.000))))			Favours [high expression] Favours [low expression]	100



	Experim	ental	Contro	bl		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H. Fixed. 95% CI	M-H. Fixed. 95% Cl
Chen 2018	28	39	10	24	3.8%	3.56 [1.22, 10.39]	
Fei 2020	11	24	2	21	1.2%	8.04 [1.52, 42.43]	
Feng 2017	15	43	10	48	6.6%	2.04 [0.80, 5.20]	
Fu 2016	26	40	17	40	6.4%	2.51 [1.02, 6.20]	
Hao 2018	22	29	14	29	3.6%	3.37 [1.10, 10.32]	
Lu 2016	28	78	14	78	9.7%	2.56 [1.22, 5.37]	
Lu 2017	17	28	8	28	3.4%	3.86 [1.26, 11.80]	
Luo 2016	7	50	1	20	1.3%	3.09 [0.36, 26.92]	
Ma 2016	14	19	8	21	2.2%	4.55 [1.18, 17.52]	
Mu 2019	21	31	8	29	2.9%	5.51 [1.82, 16.71]	
Wang 2016	19	26	10	26	2.9%	4.34 [1.34, 14.03]	
Wang 2018 (2)	17	26	16	26	6.0%	1.18 [0.38, 3.65]	
Wang 2019	10	19	6	19	3.1%	2.41 [0.64, 9.03]	
Yang 2016	33	65	27	65	14.3%	1.45 [0.73, 2.90]	
Yin 2018	38	46	18	46	3.4%	7.39 [2.81, 19.40]	
Yu 2019	30	48	17	48	6.9%	3.04 [1.32, 6.98]	
Zhang 2016	27	57	6	21	5.0%	2.25 [0.76, 6.63]	
Zhou 2016	28	81	25	81	17.6%	1.18 [0.61, 2.28]	
Total (95% CI)		749		670	100.0%	2.58 [2.05, 3.24]	•
Total events	391		217				
Heterogeneity: Chi ² =	21.05, df =	= 17 (<i>P</i> :	= 0.22); l ²	² = 19%	, o		0.01 0.1 1 10 100
Test for overall effect:							
	```		,				Favours [high expression] Favours [low expression]

Fig. 5 Forest plot of HRs for the association between high AFAP1-AS1 expression and LTS

heterogeneity ( $I^2 = 82\%$ ,  $P_Q < 0.00001$ ), a random-effects model was used. The data showed a synthesized OR of 1.59 (95% CI: 0.88–2.85; high vs. low; Fig. 8). Sensitivity analysis was performed owing to the high heterogeneity. In the sensitivity analysis, the removal of one or two articles did not reduce heterogeneity. Eight eligible studies with 850 patients reported *AFAP1-AS1* expression levels according to DM. Due to severe heterogeneity (P = 65%,  $P_Q = 0.005$ ), a random-effects model was used. These data showed a pooled OR of 1.81 (95% CI: 0.90–3.66; high *AFAP1-AS1* vs. low *AFAP1-AS1*; Fig. 9). In the sensitivity analysis, after the study by Wang *et al* ^[27] was excluded, the heterogeneity decreased (P = 30%,  $P_Q = 0.20$ ).

	Experim	ental	Contr	ol		Odds ratio	)		Odds ratio	
Study or subgroup	Events	Tota	Events	Total	Weight	M-H. Fixed. 95% Cl	I	M-H. F	ixed. 95% CI	
Chen 2018	33	39	16	24	2.0%	2.75 [0.82, 9.27]	]	-		
Dai 2018	14	17	7	19	0.8%	8.00 [1.69, 37.95]	j			_
Deng 2015	40	66	15	55	4.3%	4.10 [1.90, 8.88]	]			
Feng 2017	27	43	15	48	3.5%	3.71 [1.56, 8.85]	]			
Fu 2016	20	40	18	40	6.0%	1.22 [0.51, 2.94]	j			
Leng 2018	18	56	4	18	2.8%	1.66 [0.48, 5.76]	]			
Lu 2016	65	78	51	78	5.7%	2.65 [1.24, 5.64]	j			
Lu 2017	16	28	6	28	1.7%	4.89 [1.51, 15.79]	j			
Luo 2016	21	50	5	20	2.8%	2.17 [0.68, 6.91]	]			
Ma 2016	12	19	10	21	2.3%	1.89 [0.53, 6.69]	j			
Ma 2019	21	86	14	74	7.6%	1.38 [0.65, 2.97]	j			
Mu 2019	18	56	4	18	2.8%	1.66 [0.48, 5.76]	j			
Wang 2016	21	26	10	26	1.3%	6.72 [1.92, 23.58]	j			
Wang 2018 (1)	34	61	14	42	4.9%	2.52 [1.11, 5.70]	j			
Wang 2018 (2)	22	26	14	26	1.4%	4.71 [1.27, 17.56]	j			
Yang 2016	41	65	25	65	6.2%	2.73 [1.34, 5.56]	j			
Ye 2015	32	45	34	45	6.6%	0.80 [0.31, 2.03]	j			
Yin 2018	18	46	12	46	4.9%	1.82 [0.75, 4.41]	]			
Yu 2019	27	48	16	48	4.7%	2.57 [1.12, 5.88]	j			
Zhang 2016	26	57	11	21	5.9%	0.76 [0.28, 2.08]	j			
Zhang 2018	31	132	23	106	13.1%	1.11 [0.60, 2.04]	j			
Zhong 2020	16	37	4	36	1.5%	6.10 [1.79, 20.77]	j			
Zhou 2016	53	81	30	81	7.0%	3.22 [1.69, 6.12]	]			
Total (95% CI)		1202		985	100.0%	2.26 [1.87, 2.72]	]		•	
Total events	626		358							
Heterogeneity: Chi ² =		= 22 (P :		$^{2} = 37\%$	D					100
Test for overall effect:				2			0.01	0.1 1	10	100
	_ 5101 (						I	avours [high expression]	Favours [low expression	on]

Fig. 6 Forest plot of HRs for the association between high AFAP1-AS1 expression and HTS

	Experim	ental	Contro	b		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H. Fixed. 95% Cl	M-H. Fixed. 95% Cl
Chen 2018	22	39	10	24	4.7%	1.81 [0.65, 5.07]	
Fei 2020	9	24	0	21	0.3%	26.35 [1.42, 487.60]	· · · · · · · · · · · · · · · · · · ·
Feng 2017	13	43	15	48	8.7%	0.95 [0.39, 2.33]	
Fu 2016	19	40	18	40	8.3%	1.11 [0.46, 2.66]	
Hao 2018	21	29	17	29	4.1%	1.85 [0.62, 5.56]	
Leng 2018	37	56	10	18	4.5%	1.56 [0.53, 4.60]	
Ma 2016	8	19	13	21	6.3%	0.45 [0.13, 1.59]	
Wang 2016	14	26	9	26	3.6%	2.20 [0.72, 6.73]	
Wang 2018 (1)	25	61	9	42	5.5%	2.55 [1.04, 6.24]	
Yang 2016	39	65	35	65	12.3%	1.29 [0.64, 2.58]	
Ye 2015	13	45	9	45	5.6%	1.63 [0.61, 4.30]	
Yin 2018	40	46	35	46	4.0%	2 10 [0 70, 6 25]	
Zhang 2016	38	57	8	21	3.4%	3.25 [1.15, 9.18]	
Zhang 2018	2	132	1	106	1.0%	1.62 [0.14, 18.06]	
Zhong 2020	13	37	24	36	13.8%	0.27 [0.10, 0.71]	
Zhou 2016	23	81	22	81	13.8%	1.06 [0.53, 2.12]	
Total (95% CI)		800		669	100.0%	1.38 [1.08, 1.75]	◆
Total events	336		235				
Heterogeneity: Chi ² =		= 15 (P		= 42%	, D		0.01 0.1 1 10 100
Test for overall effect:					-		
	<u> </u>	. – 0.0	,				Favours [high expression] Favours [low expression]

Fig. 7 Forest plot of HRs for the association between high AFAP1-AS1 expression and PHG

#### **External validation**

We used R to analyze the OS, DFS, and PFS of patients with 33 cancer types associated with *AFAP1-AS1* expression. First, for OS, a fixed-effects model was used because of non-significant heterogeneity ( $I^2 = 41\%$ ,  $P_Q = 0.009$ ). The comprehensive result suggests that high

expression of *AFAP1-AS1* was associated with shorter OS (HR = 1.05, 95% CI: 1.02–1.08, Fig. 10). The relationship between *AFAP1-AS1* expression and DFS was studied in 28 of 33 tumors, and the relationship between *AFAP1-AS1* expression and PFS was studied in 32 tumors. There was no significant heterogeneity (DFS:  $I^2 = 0\%$ ,  $P_Q = 0.58$ ;

	High exp	ression	Low exp	oressio	n	Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H. Random. 95% Cl	M-H. Random. 95% CI
Chen 2018	26	39	8	24	6.9%	4.00 [1.36, 11.76]	
Dai 2018	6	17	15	19	5.7%	0.15 [0.03, 0.64]	
Deng 2015	37	66	17	55	7.8%	2.85 [1.35, 6.04]	
Feng 2017	28	43	15	48	7.5%	4 11 [1 71, 9 85]	
Fu 2016	18	40	16	40	7.5%	1.23 [0.51, 2.98]	
Ma 2016	12	19	11	21	6.3%	1.56 [0.44, 5.53]	
Ma 2019	33	86	49	74	8.1%	0.32 [0.17, 0.61]	
Mu 2019	19	31	8	29	6.9%	4.16 [1.40, 12.35]	
Wang 2019	5	19	3	19	5.4%	1.90 [0.38, 9.44]	
Ye 2015	35	45	18	45	7.4%	5.25 [2.09, 13.20]	
Yin 2018	27	46	24	46	7.6%	1.30 [0.57, 2.97]	
Yu 2019	29	48	18	48	7.6%	2.54 [1.12, 5.79]	
Zhong 2020	10	37	22	36	7.2%	0.24 [0.09, 0.63]	
Zhou 2016	55	81	32	81	8.1%	3.24 [1.70, 6.17]	
Total (95% CI)		617		585	100.0%	1.59 [0.88, 2.85]	<b>•</b>
Total events	340		256				
Heterogeneity: Tau ²		$ni^2 = 73.7$		(P < 0)	00001).	² = 82%	0.01 0.1 1 10 100
Test for overall effect				(, < 0			
rescion overall effect	z = 1.00	(1 - 0.1)	<u>~</u> )				Favours [high expression] Favours [low expression]

Fig. 8 Forest plot of HRs for the association between high AFAP1-AS1 expression and LNM

	Experime	ental	Cont	rol		Odds ratio	Odds ratio
Study or subgroup	Events	Total	Events	Total	Weight	M-H. Random. 95% Cl	M-H. Random. 95% CI
Chen 2018	11	39	3	24	11.3%	2.75 [0.68, 11.11]	
Deng 2015	43	66	25	55	16.7%	2.24 [1.08, 4.67]	
Fu 2016	3	40	5	40	10.5%	0.57 [0.13, 2.55]	
Tang 2017	43	68	9	28	15.0%	3.63 [1.43, 9.24]	
Wang 2016	15	26	4	26	11.9%	7.50 [2.01, 28.05]	
Wang 2019	4	19	11	19	11.1%	0.19 [0.05, 0.81]	
Zhang 2018	2	132	2	106	7.8%	0.80 [0.11, 5.78]	
Zhou 2016	22	81	9	81	15.7%	2.98 [1.28, 6.97]	
Total (95% CI)		471		379	100.0%	1.81 [0.90, 3.66]	
Total events	143		68				
Heterogeneity: Tau ²	= 0.63; Cł	$1i^2 = 20.2$	23, df = 7 (	P = 0.0	005); l² = 6	35%	0.01 0.1 1 10 100
Test for overall effect	ct: Z = 1.66	(P = 0.1)	0)				
			•				Favours [high expression] Favours [low expression]

Fig. 9 Forest plot of HRs for the association between high AFAP1-AS1 expression and DM

PFS:  $I^2 = 47\%$ ,  $P_Q = 0.002$ ); therefore, we chose the fixedeffects model. The *AFAP1-AS1* expression level was related to DFS (pooled HR = 1.06, 95% CI: 1.00–1.11, Fig. 11) and PFS (pooled HR = 1.04, 95% CI: 1.01–1.07, Fig. 12) in patients with various tumors.

#### **Publication bias**

Funnel plots were used to detect publication biases in the included studies. The final results showed no significant asymmetry, suggesting no obvious bias in OS (Fig. 13a), DFS (Fig. 13b), or PFS (Fig. 13c).

# Discussion

An increasing number of studies have shown that lncRNAs are abnormally expressed in tumor tissues and are involved in the occurrence and development of tumors. As a molecular blocker, lncRNA can act as a "sponge" to adsorb miRNA and block its inhibitory effect on its downstream target mRNA^[53]. AFAP1-AS1 also acts as a competitive endogenous RNA (ceRNA) that recruits miRNAs to promote tumor progression and metastasis. In endometrial cancer, AFAP1-AS1 promotes the expression of VEGFA by adsorbing miR-545-3p, thereby promoting tumor growth and metastasis ^[16]. Ma et al proposed that AFAP1-AS1 could also regulate the expression of FGF7 through the sponge absorption of miR-155-5p, thereby promoting the GC process^[40]. Fei *et al* demonstrated that AFAP1-AS1 promotes the occurrence and progression of OS through competitive binding of *miR-497* and the regulation of IGF1R expression [46]. In prostate cancer, AFAP1-AS1 enhances the proliferation, invasion, and metastasis of prostate cancer by regulating miR-512-3p27. Zhang et al showed that AFAP1-AS1 promotes TNBC cell proliferation and invasion by targeting miR-145 to regulate MTH1 expression^[54].

In addition, lncRNAs can be specifically transcribed and participate in specific signaling pathways as signal

				Hazard ratio	Hazard ratio
Study	TE	SE	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
ACC	0.49	0.2497	0.4%	1.62 [1.00; 2.65]	2
BLCA	0.05	0.0608	6.5%	1.06 [0.94; 1.19]	rin and a second se
BRCA	0.01	0.0774	4.0%	1.01 [0.87; 1.18]	in the second
CESC	-0.10	0.1357	1.3%	0.90 [0.69; 1.18]	4
CHOL	-0.08	0.1305	1.4%	0.92 [0.71; 1.19]	4
COAD	0.11	0.0686	5.1%	1.11 [0.97; 1.27]	in the second
DLBC	0.50	0.3096	0.2%	1.65 [0.90; 3.02]	P.
ESCA	-0.04	0.0745	4.3%	0.96 [0.83; 1.11]	¢.
GBM	0.19	2.1923	0.0%	1.21 [0.02; 88.75]	
HNSC	0.05	0.0461	11.3%	1.05 [0.96; 1.15]	<u> </u>
KICH	0.09	3.6141	0.0%	1.09 [0.00; 1304.69]	
KIRC	0.26	0.0890	3.0%	1.30 [1.09; 1.55]	¢
KIRP	0.51	0.1384	1.2%	1.66 [1.27; 2.18]	13
LAML	-0.03	0.1726	0.8%	0.97 [0.69; 1.36]	4
LGG	1.04	1.0898	0.0%	2.82 [0.33; 23.85]	+-
LIHC	0.07	0.0812	3.6%	1.07 [0.91; 1.25]	¢
LUAD	-0.03	0.0430	13.0%	0.97 [0.89; 1.05]	
LUSC	0.04	0.0488	10.0%	1.04 [0.95; 1.14]	*
MESO	0.08	0.0701	4.9%	1.08 [0.94; 1.24]	Ū.
OV	0.07	0.0492	9.9%	1.07 [0.97; 1.18]	
PAAD	0.16	0.0804	3.7%	1.17 [1.00; 1.37]	6
PCPG	-2.71	14.2067	0.0%	0.07 [0.00; 82750112329.78]	
PRAD	-11.71	16.0546	0.0%	0.00 [0.00; 380978038.20]	
READ	-0.15	0.4616	0.1%	0.86 [0.35; 2.12]	4
SARC	-0.25	0.3880	0.2%	0.78 [0.36; 1.67]	4
SKCM	-0.44	0.7019	0.0%	0.65 [0.16; 2.55]	+
STAD	-0.04	0.0459	11.3%	0.96 [0.88; 1.05]	
TGCT	-0.63	3.8426	0.0%	0.53 [0.00; 993.13]	
THCA	19.86	6.5691	0.0%	422722397.38 [1082.54; 165068709617817.78]	·
THYM	0.47	0.1866	0.7%	1.61 [1.11; 2.32]	a
UCEC	0.12	0.1002	2.4%	1.13 [0.93; 1.37]	d
UCS	0.09	0.1950	0.6%	1.10 [0.75; 1.61]	Ļ
UVM	-1.19	7.9657	0.0%	0.30 [0.00; 1834002.69]	
Total (959	% CI)		100.0%	1.05 [1.02; 1.08]	
Prediction				[0.94; 1.21]	
		).0035; Chi² =	= 53.83, df =	$= 32 (P < 0.01); I^2 = 41\%$	0.001
0	-	·			Low expression High expression

Fig. 10 Forest plot of HRs for the association between high AFAP1-AS1 expression and OS by external validation

transduction molecules. For example, Shi *et al* confirmed that the lncRNA *AFAP1-AS1* is overexpressed in osteosarcoma and plays a tumorigenic role in osteosarcoma through the RhoC/ROCK1/p38MAPK/Twist1 signaling pathway^[55]. *AFAP1-AS1* becomes an oncogene in TSCC by activating the Wnt/ $\beta$ -catenin signaling pathway and inhibiting the expression of EMT-related genes^[29]. In pituitary adenomas, *AFAP1-AS1* promotes tumor growth by regulating the PTEN/PI3K/AKT signaling pathway^[56].

Resistance to chemoradiotherapy is the main cause of tumor treatment failure; lncRNAs play an important role in this process. lncRNA *AFAP1-AS1* through activation of Wnt/ $\beta$ -catenin signaling pathway, which is induced by promoting cell proliferation, migration and TNBC radiation resistance ^[57]. Huang *et al* also confirmed that

*AFAP1-AS1* promoted chemotherapeutic resistance of NSCLC cells by inhibiting *miR-139-5p* expression and promoting the RRM2/EGFR/AKT signaling pathway^[58]. *AFAP1-AS1*, through the PI3K/AKT pathway, induces cisplatin resistance in NSCLC^[59].

To investigate the prognostic effect of *AFAP1-AS1* and the relationship between *AFAP1-AS1* expression and the clinicopathological features of different tumors, we performed a meta-analysis of 35 qualified articles and 3433 cases. We found that patients with high *AFAP1-AS1* expression had shorter OS, suggesting that patients with high *AFAP1-AS1* expression may have a worse prognosis. This result was reported in a previous article ^[13]. In addition, there was no obvious heterogeneity in the included articles, which may have been due

				Hazard ratio	Hazard ratio
Study	TE	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
ACC	7.30	5.6619	0.0%	1483.11 [0.02; 97852994.16]	
BLCA	0.07	0.1443	3.2%	1.08 [0.81; 1.43]	
BRCA	0.15	0.0943	7.4%	1.17 [0.97; 1.40]	ф.
CESC	-0.05	0.2089	1.5%	0.95 [0.63; 1.43]	4
CHOL	-0.29	0.2067	1.5%	0.75 [0.50; 1.12]	4
COAD	-0.16	0.2024	1.6%	0.85 [0.57; 1.27]	h
DLBC	0.92	0.6944	0.1%	2.51 [0.64; 9.78]	+
ESCA	-0.01	0.1343	3.7%	0.99 [0.76; 1.29]	
HNSC	-0.03	0.1378	3.5%	0.97 [0.74; 1.27]	4
KICH	-10.36	22.1067	0.0%	0.00 [0.00; 208257366269749.69]	
KIRC	-0.80	1.2254	0.0%	0.45 [0.04; 4.96]	+
KIRP	0.28	0.2315	1.2%	1.33 [0.84; 2.09]	(a
LGG	-9.51	4.7807	0.0%	0.00 [0.00; 0.87]	+
LIHC	0.12	0.0711	13.0%	1.13 [0.99; 1.30]	in the second
LUAD	0.03	0.0566	20.6%	1.03 [0.93; 1.16]	4
LUSC	0.13	0.0772	11.0%	1.14 [0.98; 1.33]	The second se
MESO	0.27	0.3117	0.7%	1.31 [0.71; 2.42]	Ţ
OV	-0.03	0.0681	14.2%	0.97 [0.85; 1.10]	
PAAD	0.25	0.1422	3.3%	1.29 [0.97; 1.70]	
PCPG	9.92	6.5532	0.0%	20363.10 [0.05; 7708490739.84]	
PRAD	-7.42	8.1019	0.0%	0.00 [0.00; 4701.36]	<b>_</b>
READ	0.11	0.4953	0.3%	1.11 [0.42; 2.94]	Ļ
SARC	-0.20	0.3689	0.5%	0.82 [0.40; 1.68]	+
STAD	0.04	0.0855	9.0%	1.04 [0.88; 1.23]	
TGCT	0.37	0.8494	0.1%	1.44 [0.27; 7.63]	+
THCA	4.40	6.3038	0.0%	81.36 [0.00; 18889539.98]	
UCEC	0.01	0.1407	3.3%	1.01 [0.76; 1.33]	b b
UCS	-0.11	0.5742	0.2%	0.90 [0.29; 2.77]	ł
Total (95%	S CI)		100.0%	1.06 [1.00; 1.11]	
Prediction				[1.00; 1.11]	
		Chi ² = 25.56, c	lf = 27 ( <i>P</i> = 0		تــللــ 0.001
-	-		•		Low expression High expression

Fig. 11 Forest plot of HRs for the association between high AFAP1-AS1 expression and DFS by external validation

to experimental errors, small sample sizes, too many cancer types, or different cutoff values. To eliminate heterogeneity, more experiments and sophisticated methods are required. We also observed a relationship between *AFAP1-AS1* expression and DFS and PFS; high *AFAP1-AS1* expression was associated with shorter DFS and PFS. To validate our results, we conducted external verification using R, and the results were found to be consistent with the conclusions of our meta-analysis. Therefore, we speculated that *AFAP1-AS1* could be used as a prognostic molecular marker for different types of cancer.

To examine the relationship between *AFAP1-AS1* and survival, we assessed the association between *AFAP1-AS1* and five clinicopathological features: LTS, HTS, PHG, LNM, and DM. The pooled data showed that high *AFAP1-AS1* expression was associated with LTS, HTS, and PHG, but not with LNM or DM. These results differ from those of previous studies ^[14, 18]. After accounting for data extraction errors, we analyzed the

possible reasons for the differences in this meta-analysis. The included studies and carcinoma types were recently updated, and the inclusion of new cancer types or an increased number of cancer patients may have affected the final results of this study. In this study, considering the relationship between *AFAP1-AS1* and LNM, five new cancer types were identified: TC, GC, CCRCC, PCA, and EC. Additionally, the number of NSCLC cases has increased. Two new articles have been published to study the relationship between *AFAP1-AS1* and DM, and two new cancers, PCA and TNBC, have been added. Unfortunately, the exact reason for these discrepancies remains unknown. Therefore, a larger study with an improved design is required to verify our results.

It is worth noting that the gold standard for tumor diagnosis is pathological results, but tissue-based slices cause harm to patients; therefore, most scholars focus on serological markers. At present, whether lncRNAs can be used in the early stages of tumors or whether the expression of lncRNAs differs at different tumor stages is

				Hazard ratio	Hazard ratio
Study	TE	SE	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
ACC	0.59	0.2493	0.4%	1.81 [1.11; 2.95]	+
BLCA	0.01	0.0645	5.4%	1.01 [0.89; 1.14]	¢
BRCA	0.05	0.0793	3.6%	1.05 [0.90; 1.23]	μ
CESC	0.03	0.1206	1.5%	1.03 [0.81; 1.31]	÷
CHOL	-0.13	0.1160	1.7%	0.88 [0.70; 1.10]	4
COAD	0.10	0.0605	6.1%	1.10 [0.98; 1.24]	φ.
DLBC	0.26	0.3000	0.2%	1.30 [0.72; 2.35]	<b>₽</b>
ESCA	0.00	0.0620	5.8%	1.00 [0.89; 1.13]	ф.
GBM	-0.50	2.1335	0.0%	0.61 [0.01; 39.78]	<b>-</b>
HNSC	-0.06	0.0511	8.6%	0.95 [0.86; 1.05]	¢.
KICH	-0.43	2.7790	0.0%	0.65 [0.00; 151.36]	
KIRC	0.27	0.0952	2.5%	1.31 [1.09; 1.58]	
KIRP	0.39	0.1324	1.3%	1.48 [1.14; 1.92]	*
LGG	0.40	1.0501	0.0%	1.49 [0.19; 11.69]	_ <del></del>
LIHC	0.11	0.0637	5.5%	1.12 [0.99; 1.27]	¢.
LUAD	-0.05	0.0356	17.7%	0.95 [0.89; 1.02]	Q. C.
LUSC	0.07	0.0556	7.2%	1.08 [0.96; 1.20]	ф
MESO	0.08	0.0771	3.8%	1.08 [0.93; 1.26]	¢
OV	0.04	0.0466	10.3%	1.04 [0.95; 1.14]	
PAAD	0.16	0.0727	4.2%	1.17 [1.01; 1.35]	ta da
PCPG	1.43	5.3422	0.0%	4.17 [0.00; 147192.91]	
PRAD	-2.23	2.7966	0.0%	0.11 [0.00; 25.80]	
READ	-0.36	0.4471	0.1%	0.70 [0.29; 1.68]	-+
SARC	-0.22	0.2877	0.3%	0.80 [0.46; 1.41]	*
SKCM	0.25	0.4226	0.1%	1.29 [0.56; 2.94]	- <del>-</del> -
STAD	-0.02	0.0497	9.1%	0.98 [0.89; 1.08]	<u>0</u>
TGCT	0.31	0.8162	0.0%	1.36 [0.28; 6.76]	- <b>+</b>
THCA	3.23	4.4083	0.0%	25.26 [0.00; 142800.81]	
ТНҮМ	0.59	0.1342	1.2%	1.81 [1.39; 2.35]	*
UCEC	0.02	0.0926	2.6%	1.02 [0.85; 1.22]	φ.
UCS	0.04	0.1962	0.6%	1.04 [0.71; 1.53]	+
UVM	1.85	6.1063	0.0%	6.34 [0.00; 999318.93]	,
Total (95% Prediction i			100.0%	1.04 [1.01; 1.07] [0.88; 1.32]	
		92; Chi² = 58.2	3, df = 31 ( <i>P</i>	< 0.01); l ² = 47%	0.001 0.1 1 10 1000 Low expression High expression

Fig. 12 Forest plot of HRs for the association between high AFAP1-AS1 expression and PFS by external validation

a challenge that needs to be solved urgently. In addition, attention should be paid to specificity. For example, *AFAP1-AS1* is abnormally expressed in various tumors and is involved in tumorigenesis and development. Finally, the technology's immaturity and high price prevent its clinical use. Therefore, an increasing number of clinical trials must be conducted.

Some limitations of this meta-analysis should be considered. First, all included studies were conducted in China; therefore, our data and research results cannot be applied globally. Second, the data collection may have been inadequate, as non-English articles were excluded, and the number of patients and types of cancer were not sufficient. Third, 13 articles did not mention a cutoff value for high expression, and not all articles had the same cutoff value. Fourth, different types of cancers have different degrees of heterogeneity. Fifth, although the article quality evaluation was completed by two researchers, bias may still exist. Sixth, some HRs were calculated by reconstructing survival curves instead of being extracted directly from the original study; therefore, calculation errors may exist.

## Conclusion

We comprehensively searched three databases for relevant studies and according to the inclusion and exclusion criteria, 35 studies with 3433 patients were included in this meta-analysis. It was concluded that an elevated level of lncRNA *AFAP1-AS1* in cancer patients was associated with shorter OS, DFS, and PFS, and that *AFAP1-AS1* was associated with LTS, HTS, and PHG in cancer patients but not with LNM or DM. Further studies




Fig. 13 Funnel plot analysis of potential publication bias in the survival and clinicopathological parameters group. (a) OS, (b) DFS, (c) PFS

are needed to validate the association between *AFAP1-AS1* expression, prognosis, and pathological features in patients with cancer.

#### Acknowledgments

Not applicable.

## Funding

Supported by grant from the "Ten Thousand Plan" Youth Talent Project in Yunnan Province (no grant number is applicable).

# **Conflicts of interest**

The authors indicated no potential conflicts of interest.

# Authors' contributions

All authors contributed to data acquisition and interpretation and reviewed and approved the final version of this manuscript.

# Data availability statement

Data supporting the findings of this study are available from the corresponding author upon reasonable request.

# **Ethical approval**

Not applicable.

# References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
- Sanchez Calle A, Kawamura Y, Yamamoto Y, et al. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093-2100.
- Statello L, Guo CJ, Chen LL, et al. Gene regulation by long noncoding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96-118.
- Santosh B, Varshney A, Yadava PK. Non-coding RNAs: biological functions and applications. Cell Biochem Funct. 2015;33(1):14-22.
- Zhang Y, Wang LJ, Li WF, et al. The prognostic value of HOTAIR for predicting long-term prognosis of patients with gastrointestinal

cancers. Medicine (Baltimore). 2018;97(26):e11139.

- Zhang F, Li J, Xiao H, et al. AFAP1-AS1: A novel oncogenic long noncoding RNA in human cancers. Cell Prolif. 2018;51(1):e12397.
- Wu W, Bhagat TD, Yang X, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2013;144(5):956-966.e4.
- Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904-914.
- Zhang JY, Weng MZ, Song FB, et al. Long noncoding RNA AFAP1-AS1 indicates a poor prognosis of hepatocellular carcinoma and promotes cell proliferation and invasion via upregulation of the RhoA/ Rac2 signaling. Int J Oncol. 2016;48(4):1590-1598.
- Yu S, Yang D, Ye Y, et al. Long noncoding RNA actin filamentassociated protein 1 antisense RNA 1 promotes malignant phenotype through binding with lysine-specific demethylase 1 and repressing HMG box-containing protein 1 in non-small-cell lung cancer. Cancer Sci. 2019;110(7):2211-2225.
- He J, Wu K, Guo C, et al. Long non-coding RNA AFAP1-AS1 plays an oncogenic role in promoting cell migration in non-small cell lung cancer. Cell Mol Life Sci. 2018;75(24):4667-4681.
- Yin D, Lu X, Su J, et al. Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non-small cell lung cancer cell proliferation by epigenetically repressing p21 expression. Mol Cancer. 2018;17(1):92.
- Zhou Y, Chen S, Cheng S, et al. The prognostic value of high LncRNA AFAP1-AS1 expression in various cancers: A systematic review and meta-analysis containing 21 studies. Clin Chim Acta. 2018;481:147-153.
- Liu FT, Xue QZ, Zhu PQ, et al. Long noncoding RNA AFAP1-AS1, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis. Onco Targets Ther. 2016;9:4247-4254.
- Yang SL, Lin RX, Si LH, et al. Expression and functional role of long non-coding RNA AFAP1-AS1 in ovarian cancer. Eur Rev Med Pharmacol Sci. 2016;20(24):5107-5112.
- Zhong Y, Wang Y, Dang H, et al. LncRNA AFAP1-AS1 contributes to the progression of endometrial carcinoma by regulating miR-545-3p/ VEGFA pathway. Mol Cell Probes. 2020;53:101606.
- Zhuang Y, Jiang H, Li H, et al. Down-regulation of long non-coding RNA AFAP1-AS1 inhibits tumor cell growth and invasion in lung adenocarcinoma. Am J Transl Res. 2017;9(6):2997-3005.
- Liu RH, Wang MY, Chen LY, et al. Meta-analysis of the prognostic value of long non-coding RNA AFAP1-AS1 for cancer patients in China. Oncotarget. 2017;9(8):8100-8110.
- 19. Parmar MK, Torri V, Stewart L. Extracting summary statistics to

perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834.

- Wang W, Yuan F, Xu J. The prognostic role of long noncoding RNA CRNDE in cancer patients: a systematic review and meta-analysis. Neoplasma. 2019;66(1):73-82.
- Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
- Oremus M, Oremus C, Hall GB, et al. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open. 2012;2(4):e001368.
- Zhao H, Zhang K, Wang T, et al. Long non-coding RNA AFAP1antisense RNA 1 promotes the proliferation, migration and invasion of gastric cancer cells and is associated with poor patient survival. Oncol Lett. 2018;15(6):8620-8626.
- Zhou XL, Wang WW, Zhu WG, et al. High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Mol Carcinog. 2016;55(12):2095-2105.
- Tang Y, He Y, Shi L, et al. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017;8(24):39001-39011.
- Wang F, Ni H, Sun F, et al. Overexpression of IncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. Biomed Pharmacother. 2016;81:152-159.
- Wang K, Sun H, Sun T, et al. Long non-coding RNA AFAP1-AS1 promotes proliferation and invasion in prostate cancer via targeting miR-512-3p. Gene. 2020;726:144169.
- Wang Y, Lan Q. Long non-coding RNA AFAP1-AS1 accelerates invasion and predicts poor prognosis of glioma. Eur Rev Med Pharmacol Sci. 2018;22(16):5223-5229.
- Wang ZY, Hu M, Dai MH, et al. Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/β-catenin signaling pathway. Mol Cancer. 2018;17(1):3.
- Ye Y, Chen J, Zhou Y, et al. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. J Transl Med. 2015;13:137.
- Zeng Z, Bo H, Gong Z, et al. AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumour Biol. 2016;37(1):729-737.
- Zhang K, Liu P, Tang H, et al. AFAP1-AS1 promotes epithelialmesenchymal transition and tumorigenesis through Wnt/β-catenin signaling pathway in triple-negative breast cancer. Front Pharmacol. 2018;9:1248.
- He J, Wu K, Guo C, et al. Long non-coding RNA AFAP1-AS1 plays an oncogenic role in promoting cell migration in non-small cell lung cancer. Cell Mol Life Sci. 2018;75(24):4667-4681.
- Leng X, Ding X, Wang S, et al. Long noncoding RNA AFAP1-AS1 is upregulated in NSCLC and associated with lymph node metastasis and poor prognosis. Oncol Lett. 2018;16(1):727-732.
- Li Q, Dai Y, Wang F, et al. Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer. Neoplasma. 2016;63(6):977-983.
- Li R, Liu S, Li Y, et al. Long noncoding RNA AFAP1-AS1 enhances cell proliferation and invasion in osteosarcoma through regulating miR-4695-5p/TCF4-β-catenin signaling. Mol Med Rep. 2018;18(2):1616-1622.
- 37. Lu X, Zhou C, Li R, et al. Long noncoding RNAAFAP1-AS1 promoted

tumor growth and invasion in cholangiocarcinoma. Cell Physiol Biochem. 2017;42(1):222-230.

- Lu X, Zhou C, Li R, et al. Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma. Tumour Biol. 2016;37(7):9699-9707.
- Ma D, Chen C, Wu J, et al. Up-regulated IncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer. Breast Cancer. 2019;26(1):74-83.
- Ma HW, Xi DY, Ma JZ, et al. Long noncoding RNA AFAP1-AS1 promotes cell proliferation and metastasis via the miR-155-5p/FGF7 axis and predicts poor prognosis in gastric cancer. Dis Markers. 2020;2020:8140989.
- Mu Z, Dong D, Wei N, et al. Silencing of IncRNA AFAP1-AS1 inhibits cell growth and metastasis in clear cell renal cell carcinoma. Oncol Res. 2019;27(6):653-661.
- Bo H, Fan L, Li J, et al. High expression of IncRNA AFAP1-AS1 promotes the progression of colon cancer and predicts poor prognosis. J Cancer. 2018;9(24):4677-4683.
- Chen B, Li Q, Zhou Y, et al. The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a. Cell Cycle. 2018;17(16):1949-1966.
- Dai W, Tian Y, Jiang B, et al. Down-regulation of long non-coding RNA AFAP1-AS1 inhibits tumor growth, promotes apoptosis and decreases metastasis in thyroid cancer. Biomed Pharmacother. 2018;99:191-197.
- 45. Deng J, Liang Y, Liu C, et al. The up-regulation of long non-coding RNA AFAP1-AS1 is associated with the poor prognosis of NSCLC patients. Biomed Pharmacother. 2015;75:8-11.
- Fei D, Zhang X, Lu Y, et al. Long noncoding RNA AFAP1-AS1 promotes osteosarcoma progression by regulating miR-497/IGF1R axis. Am J Transl Res. 2020;12(5):2155-2168.
- 47. Feng Y, Zhang Q, Wang J, et al. Increased IncRNA AFAP1-AS1 expression predicts poor prognosis and promotes malignant phenotypes in gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21(17):3842-3849.
- Fu XL, Liu DJ, Yan TT, et al. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Sci Rep. 2016;6:33535.
- Gui JQ, Zhang C, Yang HB, et al. LncRNA AFAP1-AS1 promotes proliferation ability and invasiveness of bladder cancer cells. Eur Rev Med Pharmacol Sci. 2020;24(17):8747-8755.
- Hao F, Mou Y, Zhang L, et al. LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma. Biosci Rep. 2018;38(3):BSR20180384.
- Ma F, Wang SH, Cai Q, et al. Overexpression of LncRNAAFAP1-AS1 predicts poor prognosis and promotes cells proliferation and invasion in gallbladder cancer. Biomed Pharmacother. 2016;84:1249-1255.
- Tang J, Zhong G, Wu J, et al. Long noncoding RNA AFAP1-AS1 facilitates tumor growth through enhancer of zeste homolog 2 in colorectal cancer. Am J Cancer Res. 2018;8(5):892-902.
- Zhang MW, Zhu ZH, Xia ZK, et al. Comprehensive circRNA-microRNAmRNA network analysis revealed the novel regulatory mechanism of Trichosporon asahii infection. Mil Med Res. 2021;8(1):19.
- Zhang X, Zhou Y, Mao F, et al. IncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression. Sci Rep. 2020;10(1):7662.
- Shi D, Wu F, Mu S, et al. LncRNAAFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway. J Exp Clin

Cancer Res. 2019;38(1):375.

- Tang H, Hou B, Ye Z, et al. Knockdown of long non-coding RNA AFAP1-AS1 inhibits growth and promotes apoptosis in pituitary adenomas. Int J Clin Exp Pathol. 2018;11(3):1238-1246.
- Bi Z, Li Q, Dinglin X, et al. Nanoparticles (NPs)-meditated IncRNA AFAP1-AS1 silencing to block Wnt/β-catenin signaling pathway for synergistic reversal of radioresistance and effective cancer radiotherapy. Adv Sci (Weinh). 2020;7(18):2000915.
- Huang N, Guo W, Ren K, et al. LncRNAAFAP1-AS1 supresses miR-139-5p and promotes cell proliferation and chemotherapy resistance of non-small cell lung cancer by competitively upregulating RRM2.

Front Oncol. 2019;9:1103.

 Liu Y, Hu Q, Wang X. AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway. Oncol Lett. 2020;19(1):1024-1030.

## DOI 10.1007/s10330-022-0581-1

Cite this article as: Zhu LX, Yan JW, Xu GQ, et al. Prognostic value of the long noncoding RNA *AFAP1-AS1* in cancers. Oncol Transl Med. 2023;9(3):133–146.